利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.015 秒)

    USE OF PROCALCITONIN (PCT) IN PROGNOSIS FOLLOWING ACUTE CORONARY SYNDROMES
    11.
    发明公开
    USE OF PROCALCITONIN (PCT) IN PROGNOSIS FOLLOWING ACUTE CORONARY SYNDROMES 有权
    VERWENDUNG VON PROCALCITONIN ZUR PROGNOSE FOLGENDER AKUTER KORONARSYNDROMEN

    公开(公告)号：EP2255202A1

    公开(公告)日：2010-12-01

    申请号：EP09719129.0

    申请日：2009-01-29

    申请人： BRAHMS Aktiengesellschaft

    发明人： BERGMANN, Andreas ,  STRUCK, Joachim ,  NG, Leong Loke

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2800/324

    摘要： Subject of the present invention are assays and
    in
    vitro methods for determining a prognosis for a patient having an acute coronary syndrome, whereby the level of procalcitonin or fragments thereof is measured in a sample obtained from said patient. Said level of procalcitonin or fragments thereof may then be correlated to a predisposition to an adverse outcome of said acute coronary syndrome.

    摘要翻译： 本发明的主题是用于确定具有急性冠状动脉综合征的患者的预后的测定和体外方法，由此在从所述患者获得的样品中测量降钙素原或其片段的水平。 所述降钙素原或其片段的水平可以与所述急性冠状动脉综合征的不良结果的倾向相关。

    IN VITRO VERFAHREN ZUR DIAGNOSE UND FRÜHDIAGNOSE VON NEURODEGENERATIVEN ERKRANGUNGEN
    13.
    发明公开
    IN VITRO VERFAHREN ZUR DIAGNOSE UND FRÜHDIAGNOSE VON NEURODEGENERATIVEN ERKRANGUNGEN 有权
    体外方法进行诊断和早期诊断神经退行性ERKRANGUNGEN的

    公开(公告)号：EP2016418A1

    公开(公告)日：2009-01-21

    申请号：EP07725231.0

    申请日：2007-05-15

    申请人： BRAHMS Aktiengesellschaft

    发明人： BERGMANN, Andreas ,  ERNST, Andrea ,  HAMPEL, Harald

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6896 ,  G01N2800/28

    摘要： An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.

    Method for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
    17.
    发明公开
    Method for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists 有权
    Verfahrenfürdie诊断von schwerkranken Patienten

    公开(公告)号：EP1619505A2

    公开(公告)日：2006-01-25

    申请号：EP04019308.8

    申请日：2004-08-13

    申请人： BRAHMS Aktiengesellschaft

    发明人： Bergmann, Andreas, Dr. ,  Struck, Joachim, Dr. ,  Morgenthaler, Nils G.

    IPC分类号： G01N33/74 ,  A61K38/22 ,  A61P9/00

    CPC分类号： A61K38/2285 ,  G01N33/74 ,  G01N2333/575 ,  G01N2333/5754

    摘要： The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.

    摘要翻译： 使用重症患者体液中前肾上腺髓质素（pro-ADM）/原内皮素（pro-end）免疫反应性浓度的比例，用于诊断，病程控制和预后，包括对死亡风险的评估， 严重威胁生命的疾病。 此外，提供了治疗具有高水平的pro-ADM但具有包含血管收缩性内皮素或其前体的药物和/或内皮缩血管激动剂或肾上腺髓质素拮抗剂的pro-END免疫反应性水平不足的危重患者。

    Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes
    19.
    发明公开
    Use of Procalcitonin (PCT) in prognosis following acute coronary syndromes 审中-公开
    Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen

    公开(公告)号：EP2101178A1

    公开(公告)日：2009-09-16

    申请号：EP08152651.9

    申请日：2008-03-12

    申请人： BRAHMS Aktiengesellschaft

    发明人： Bergmann, Andreas ,  Struck, Joachim ,  Ng, Leong Loke

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2800/324

    摘要： Subject of the present invention are assays and in vitro methods for determining a prognosis for a patient having an acute coronary syndrome, whereby the level of procalcitonin or fragments thereof is measured in a sample obtained from said patient. Said level of procalcitonin or fragments thereof may then be correlated to a predisposition to an adverse outcome of said acute coronary syndrome.

    摘要翻译： 本发明的主题是用于确定具有急性冠状动脉综合征的患者的预后的测定和体外方法，由此在从所述患者获得的样品中测量降钙素原或其片段的水平。 所述降钙素原或其片段的水平可以与所述急性冠状动脉综合征的不良结果的倾向相关。